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Background: Airway inflammation stimulates proliferation of airway smooth muscle cell, which contributes to the
development of hyperplasia and hypertrophy of smooth muscle cell. The increase in airway smooth muscle cell
mass is believed to be due to an up-regulation of inflammatory mediators in the airway. It is now well recognized
that chronic inflammation as well as airway hyper-responsiveness and remodeling of airway during inflammation,
are crucial to asthma. Airway hyper-responsiveness is caused by increased cell proliferation or by hypertrophy of
airway smooth muscle cell depending on the nature of the inflammatory stimulation. Airway smooth muscle cell
proliferation in asthma is regulated by the proinflammatory cytokines including IL-1β and TNF-α. These
proinflammatory cytokines have been shown to influence human airway smooth muscle cell proliferation in vitro,
which is due to cyclooxygenase-2 expression, production of prostaglandin E2, and increased cAMP levels.
Conclusions: This review highlights the role of different proinflammatory cytokines in regulating airway smooth
muscle cell growth and also focuses on regulation of differential gene expression in airway smooth muscle cell by
growth factors and cytokines, also to bestow unique insight into the effects of conventional asthma therapies on
airway smooth muscle cell proliferation and development of new therapeutic strategies to control asthma.
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Background
Asthma is a chronic, inflammatory disease of the lung
characterized by intermittent airway obstruction, airway
hyper-responsiveness, presence of activated inflammatory
cells, inflammatory mediators, and remodeling in the air-
way [1-3]. Clinically, asthmatic patients show shortness
of breath, wheezing, coughing, and chest tightness and
decreased forced expiratory volume in one second, which
is reversible with β-adrenergic receptor agonist adminis-
tration. The role of inflammation in the pathogenesis of
asthma has been reported by Tulic et al. [4] and the
presence of inflammatory cell infiltration within the
asthmatic airway suggests the contribution of the inflam-
matory process to asthma pathogenesis [4,5]. Airway
hyper-responsiveness is results in enhanced airway nar-
rowing in asthma patients [6]. Inflamed airway secretes
histamine, thrombin, endothelin, tachykinins, and leuko-
trienes to mediate airway contraction [5,7,8]. It has beenCorrespondence: afzal@stanford.edu
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reproduction in any medium, provided the orreported that inflammatory cytokines IL-1β and TNF-α
increase the expression of bradykinin, tachykinins and
leukotrienes receptors and Gαq and Gαi proteins, which
can increase the contractility of airway smooth muscle
cell (ASM) [9-12]. The increased in Gi protein-coupled
receptor signaling has also been shown to activate Rho
guanine nucleotide exchange factors and Rho, which can
lead to contractile or calcium “sensitization”. Increased ex-
pression of myosin light chain kinase, RhoA and Gα12/
Gα13 has been reported in allergic inflammation model of
animal as well as in clinical patients [13]. Additionally,
Glycoprotein YKL-40 remains elevated in asthmatic
patients [14] and it leads to a significant increase in IL-8
production, which is dependent on MAPK (JNK and
ERK), and NF-kB pathways activation [15,16].Airway inflammation
Inflammation is defined by infiltration of the airway by in-
flammatory cells including eosinophils, mast cell, mono-
cytes, lymphocytes, active complement fragments (C3a and
C5a), and neutrophils, which contribute to elevated levels
of inflammatory mediators and procontractile stimulantsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and contraction of ASM [22]. It has been reported that
C3a plays a crucial role in asthma primarily by regulating
mast cell-ASM cell interaction. In clinical conditions of
asthma, both infections and allergens of respiratory tract
cause a local complement activation. The complement fac-
tors C3a and C5a play a central role in asthma pathogen-
esis because of their ability to recruit and activate
leukocytes, increase vascular permeability, stimulate con-
traction of smooth muscle, and trigger degranulation of
mast cells. It has been reported that bronchoalveolar lavage
of asthma individuals contains quantitative higher levels of
both C3a and C5a as compared with healthy controls. It
has also been demonstrated that ASM cells modulate air-
way inflammation by release of cytokines and chemokines
and they express receptors and adhesion molecules that
modulate inflammatory cell trafficking and function. When
exposed to IL-1β, TNF-α, IFN-γ, IL-4, IL-13, and bradyki-
nin inflammatory mediators in-vitro, ASM cells have been
shown to release IL-8, eotaxin, monocyte chemoattractant
proteins (MCP)-1, -2, and −3, GM-CSF, IL-5, regulated
upon activation, normal T-cell expressed and secreted
(RANTES, CCL-5), IL-6 and other IL-6 family cytokines
including leukemia inhibitory factor (LIF) and IL-11
[23,24]. In addition to this, few studies reported ex-
pression of RANTES and eotaxin in ASM cells in bron-
chial biopsies from asthmatic patients, and suggested that
ASM cells also exhibit these synthetic functions in-vivo
[25]. These cytokines specifically modulate migration and
survival of eosinophils, mast cells, monocytes, and lym-
phocytes, as well as immunoglobin production. ASM also
expresses intracellular adhesion molecule-1 and vascular
cell adhesion molecule-1 (VCAM1), CD44, as well as
integrins, which allow interaction with T cells and en-
hance T cell survival or modulate T cell inflammatory
functions [26,27].
Airway remodeling
It has been reported from human autopsy and biopsy
studies that the degree of airway remodeling is asso-
ciated with abundance of inflammatory cells and media-
tors in the airway [6,17,19]. In addition, few researches
have shown increased vascularity of the airway, which
may contribute to thickening of the airway wall. How-
ever, in both human asthmatics and animal models of
asthma, increased ASM mass has been reported but
mechanisms of this pathological condition are still not
well clear. A number of researches have suggested that
TGF-β appears to induce ASM hypertrophy [25]. In
spite of the relative contribution of hyperplasia or hyper-
trophy, all asthma conditions show altered airway me-
chanics and increased airway resistance. The actual
underlying relationship between inflammation and air-
way remodeling is due to either chronic inflamma-tion as seen in animal model of asthma and in airway
eosinophilia in wheezing of young children, suggesting
that remodeling may be an early pathogenic mechanism
[6,17,19,25,28,29]. In addition to the functional changes
associated with ASM, the structural changes are also
playing a crucial role in promoting excessive airway nar-
rowing as seen in elastolytic mouse model of emphy-
sema [30,31]. Increase in airway wall thickness, ECM
remodeling, and detachment from the lung parenchyma
and elastic recoil of the lung are supposed to alter the
tension on ASM allowing for enhanced shortening and
greater degree of airway narrowing [32]. In spite of this,
the major effect of airway remodeling is due to an in-
crease in ASM mass and the changes associated with air-
way geometry during airway contraction [32,33] (Figure 1).
Mechanisms of ASM proliferation
Initial studies of the role of ASM in asthma focused on
examining contractile properties of ASM cells isolated
from animal or human trachea. Eosinophils have been
hallmark of asthma inflammation and actively contribute
in ASM cell proliferation and cell mass [34]. In-vitro cul-
ture has shown that ASM preserves functional responses
to specific stimulant including bradykinin, thromboxane
A2, histamine, leukotriene D4, platelet derived growth
factor α, or β-agonists, as well as expresses ion channels
[1]. Epidermal growth factor, platelet derived growth fac-
tor and basic fibroblast growth factor activate receptor
tyrosine kinase and have shown potent ASM mitogenic
properties in vitro. In ASM cells, subsequent activation
of receptor tyrosine kinase, phosphoinositide-3 kinase
and p42/p44 extracellular signal-regulated kinases re-
sults in initiation of ASM proliferation. G protein cou-
ples receptors have also been shown to stimulate ASM
proliferation and their levels are found elevated in the
asthmatic airway. Additionally, GPCR ligands have been
reported to up regulate growth factor-stimulated growth
of human ASM and co-stimulation of ASM cells with
epidermal growth factor and thrombin, histamine or car-
bachol induce ASM cell proliferation. These stimulatory
signals were found to increase GPCR mediated activa-
tion of phosphoinositide-3 kinase. Other mediators
including the cytokines, chemokines and cytokine recep-
tors also play a crucial role in asthma pathogenesis and
development of ASM proliferation. Chemokines mainly
recruit immune cells to the site of inflammation. Che-
mokine receptors have been classified according to their
function, and CCR3 is the most relevant receptor and it
controls eosinophil recruitment by eotaxin and is also
expressed on lymphocytes. Newly tested antisense oligo-
nucleotides bind (TPI ASM-8) to complimentary mRNA
of chemokine receptors CCR3 [35], thereby suppressing
gene transcription. In most of research findings in
asthma models and clinical samples, it has been reported
Figure 1 Model illustrates how Th2 driven cytokines induce airway hyper-responsiveness and obstruction in asthma condition.
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IL-6 play a crucial role due to their possible role in air-
way remodeling. The treatment of ASM with IL-1α and
TNF-α attenuated the mitogenic effects of bFGF and
thrombin, but strongly increased mitogen-stimulated
growth in presence of indomethacin or dexamethasone,
which was associated with suppression of COX-2 ex-
pression and PGE2 production. A substantial documen-
tary evidence supports IL-1β and TNF-α as a central
players in the pathogenesis and progression of asthma;
they are also common in any inflammatory disorder,
and can act both locally and systemically. Elevated
levels of IL-1β and TNF-α are reported from BAL
fluid of asthma patients and they increase with severity
of disease. IL-1β and TNF-α have been shown to act
on airway inflammatory cells, and modulate effects of
other cytokines and ASM cells. IL-1β also functions in
cooperation with other cytokines such as IL-5 or GM-
CSF, promotes eosinophil survival, and modulates
ASM function. It has been reported that stimulation of
ASM cells with IL-1β or IL-1β and TNF-α leads to
sensitization of adenylatecyclase and elevated cAMP
production in response to Gs protein-coupled receptor
stimulation. The regulatory effects of IL-1β and TNF-α
on ASM cell proliferation could have important conse-
quences for development of asthma therapeutics.
Drugs such as (COX-2-targeting) non-steroidal anti-in-
flammatory drugs and glucocorticosteroids are often
used to treat inflammation-based diseases but their use
is associated with significant side effects. The ability of
glucocorticosteroids to suppress ASM COX-2 and
PGE2 induction caused by inflammatory agents such
as IL-1β and TNF-α could represent a deleterious ef-
fect of glucocorticosteroids treatment.Conclusions
Airway diseases are characterized by changes in compos-
ition of the airway wall; in fact, these changes are
believed to be largely responsible for the various features
of those diseases. For example, asthma is characterized
by wall thickening (including both increased ASM and
connective tissue) and ASM hyper-responsiveness. In-
flammation causes airway hyper-responsiveness by up-
regulation of procontractile agonists in the airway,
increased expression of receptors, their signaling inter-
mediates, and effectors, as well as regulators of calcium
stores in ASM.
Studies of the airways in health and disease often use in-
dices of the degree of ASM contraction: e.g., measures of
airflow resistance in patients (forced expiratory volume in
1 second, FEV1) or animal models, airway narrowing in
lung slices, or grams tension in isolated ASM strips
[30,31]. Increased ASM mass, seen in asthma and various
animal models of asthma, is expected to manifest as
changes not only in the magnitudes of airway narrowing,
but also in the rates of narrowing [30,31]. Thus in asthma,
ASM appears to cooperate in most known pathogenic
processes. ASM is central to the development of Airway
Hyper-Reactivity (AHR) being the target and effector of
procontractile agonists. Increases in ASM mass affecting
airway geometry and mechanics, in conjunction with con-
tractile sensitization, have profound effects on airway
lumen size and resistance to airflow. Through both direct
and indirect effects on other resident and infiltrating air-
way cells, ASM plays an important role in modulating the
inflammatory response, and thereby promotes many of
the features of airway remodeling. Likely asthma is caused
by interactions between genetic and environmental agents,
but its pathogenesis is still not well known. Clinically,
Figure 2 Model illustrates details of asthma treatment strategies.
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CD4+ T (Th2 subtype) cells in the airways. These Th2
lymphocytes produce IL-4, IL-5, IL-9, and IL-13 which
mediate the inflammatory response in asthmatic airways
by recruiting and activating additional Th2 cells and also
mast cells and eosinophils. Serine and matrix metallopro-
teinase have been reported as one of the crucial agents in
asthma pathogenesis. A number of new therapeutic targets
to rescue patients from asthma are underway. Omalizu-
mab is a recombinant humanized monoclonal antibody
that is proven to be effective for patients with moderate-
to-severe persistent asthma [36,37]. Omalizumab binds to
IgE and produces anti-inflammatory effects in allergen
challenge and bronchial biopsy protocols supported the
role that IgE plays in airway inflammation in asthma [38].
TNF-α also is up-regulated in asthma and promotes re-
cruitment of neutrophils and eosinophils into the airways
[5,29,34]. Etanercept a recombinant fusion protein that
blocks TNF-α, produces marked and significant improve-
ment in asthma control when added to high-dose ICS
therapy in patients with treatment-resistant asthma
[39,40]. The anti-TNF-α monoclonal antibody infliximab
shows positive outcomes in moderate asthma despite ICS
therapy [41]. Other therapies include selective inhibition of
Cyclic adenosine monophosphate (cAMP), Macrolides and
ketolides antibiotics, Adenosine A2B antagonists [42,43],
Chemokine/chemokine receptor antagonists [44,45],
prostanoid and F2-isoprostane antagonists, peroxisome
proliferator-activated receptor gamma agonists, nitric
oxide donors and inducible nitric oxide synthase inhi-
bitors, and toll-like receptor modulators (Figure 2). A
novel antisense oligonucleotide, TPI ASM-8, has been
targeted against CCR3 [35] and other chemokine recep-
tors β-chain of the proinflammatory cytokines IL-3, IL-5
and GM-CSF, which are involved in Th2 inflammation.
TPI ASM-8 is an inhaled therapy allowing specifictargeting to the lungs of a therapy that acts by different
mechanisms to inhibit the activity of eosinophils and other
Th2 cells, such as mast cells and basophils. These agents
modulate inflammatory cell function and/or reduce airway
inflammation in experimental models [39,46-48]. The last
few years have seen a concerted effort by the National
Institutes of Health and other agencies to manage asthma.
The therapeutic and attitudinal advances in managing
asthma have been very substantial in the past 15–20 years,
resulting in more effective and safer ways of controlling it.
In summary, development of new research findings
of asthma pathophysiology will help in designing novel
therapeutic targets for asthma cure.
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